International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 10 Issue 5, Sep-Oct 2026 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Anemia in Chronic Kidney Disease (CKD): An Integrated Ayurveda-Modern Pathophysiological Perspective

Dr. Maitri Pandya

PG Scholar, Department of Samhita and Maulik Siddhant,
National Institute of Ayurveda (DU), Jaipur, Rajasthan, India

ABSTRACT

Anemia is a frequent and debilitating complication of Chronic Kidney Disease (CKD), significantly worsening morbidity, cardiovascular risk, and overall mortality. While modern nephrology attributes CKD-associated anemia primarily to relative erythropoietin (EPO) deficiency, iron dysregulation, and uremic bone marrow suppression, classical Ayurvedic literature offers a sophisticated, systems-biology framework. This framework parallels modern insights through concepts such as *Mutravaha srotodusṭi* (pathology of the renal channels), *Medovaha srotas* involvement, *Pitta* predominance, and subsequent *Rakta-kṣaya* (*Pāṇḍu*). This article bridges classical Ayurvedic pathomechanics (*samprapti*) with contemporary molecular pathophysiology, providing an exhaustive, narrative-format reference for medical and scientific professionals based on classical source correlations.

How to cite this paper: Dr. Maitri Pandya "Anemia in Chronic Kidney Disease (CKD): An Integrated Ayurveda-Modern Pathophysiological Perspective" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-10 | Issue-5, October 2026, pp.978-981, URL: www.ijtsrd.com/papers/ijtsrd142172.pdf

IJTSRD142172

Copyright © 2026 by author (s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

1. INTRODUCTION

Chronic Kidney Disease (CKD) represents a progressive, irreversible loss of renal function accompanied by complex metabolic, endocrine, and inflammatory derangements. Among its multisystem manifestations, anemia is a hallmark clinical feature that correlates inversely with declining glomerular filtration rate (GFR). In modern biomedicine, the etiology is multifactorial: decreased synthesis of erythropoietin by peritubular fibroblast-like cells, functional and absolute iron deficiency mediated by elevated hepcidin (an acute-phase reactant driven by chronic inflammation), shortened erythrocyte survival due to uremic toxins, and bone marrow hyporesponsiveness. Concurrently, classical Ayurveda conceptualizes renal pathology through the lens of *Mutravaha srotodusṭi* and *Vṛkka* impairment. By examining how Ayurvedic pathogenetic mechanisms map onto contemporary molecular pathways, clinicians can gain deeper insight into multi-organ involvement, cachexia, and marrow failure in CKD.

2. Methodology

2.1. Study Design and Conceptual Framework

This paper adopts a qualitative, analytical, and translational research design, structured to bridge classical *Samprapti* with contemporary molecular and clinical nephrology. The investigation utilizes a comparative, integrative systems-biology approach to map ancient textual constructs of disease onto modern pathophysiological mechanisms associated with Anemia in Chronic Kidney Disease (CKD).

2.2. Data Sources and Classical Literature Retrieval

Primary textual data were derived from authoritative classical Ayurvedic literature and standard commentaries. Specifically, references were retrieved from the Charaka Samhita of Agnivesha (along with the *Ayurveda Dipika* commentary by Chakrapāṇi Datta), edited by Acharya Trikamji Y. (Varanasi: Chowkhambha Surabharati Prakashan). Key focal chapters and verses analyzed include:

- *Vimāna Sthāna*, Chapter 5 (*Srotovimāniya Adhyāya*)

- *Chikitsā Sthāna*, Chapter 16 (*Pāṇḍuroga Chikitsitam*)

2.3. Modern Biomedical Literature and Correlation Parameters

Modern pathophysiological data were synthesized from current nephrological principles governing CKD-associated anemia, focusing on:

- Endocrine dysfunction (reduced erythropoietin synthesis by peritubular cells).
- Systemic inflammation (cytokine networks such as IL-6, TNF-alpha, and IL-1beta).
- Iron homeostasis and regulation (hepcidin-mediated reticuloendothelial iron sequestration and functional iron deficiency).
- Metabolic abnormalities and systemic catabolism (protein-energy wasting, uremic toxin accumulation, and shortened erythrocyte survival).

2.4. Analytical and Synthesis Procedure

The integration and mapping process followed a structured tripartite analytical protocol:

- Textual Extraction & Interpretation: Classical Ayurvedic terms concerning renal-urinary channels (*Mutravaha srotas*), metabolic channels (*Medovaha srotas*), nutritive transport (*Rasavaha srotas*), and blood tissue depletion (*Rakta-kṣaya / Pāṇḍu*) were translated and interpreted contextually using structural frameworks provided by Chakrapāṇi.
- *Samprapti* Mapping: Classical concepts of *doṣa-dūṣya sammūrcchā* (pathogenic interaction), *Pitta-pradhāna doṣa-duṣṭi*, and tissue degeneration (*dhātu-pāka*) were cross-examined against modern molecular equivalents (e.g., chronic low-grade systemic inflammation, oxidative stress, and uremic tissue injury).
- Synthesis of Integrated *Samprapti*: A sequential, multi-tiered pathogenetic cascade was structured to demonstrate how localized renal failure (*Vṛkka* and *Mutravaha srotoduṣṭi*) systematically triggers metabolic, nutritional, and marrow-suppressive failures, resulting in the clinical phenotype of CKD anemia (*Pāṇḍu*).

3. Detailed Pathophysiological Dimensions (Ayurvedic-Modern Correlates)

3.1. Renal Localization and Endocrine-Metabolic Failure

The primary pathology of CKD-associated anemia is fundamentally rooted in *Mutravaha srotoduṣṭi*, where structural and functional impairment situated in the *Vṛkka* and *Mutravaha srotas* leads directly to reduced erythropoietin production, toxin retention, and systemic metabolic dysregulation. This local renal injury extends profoundly into systemic networks because the *Vṛkka* acts as the *mūlasthāna* (root locus) of the *Medovaha srotas*, [1] establishing a direct metabolic linkage. Consequently, renal involvement produces severe systemic nutritional and metabolic abnormalities, including protein-energy wasting, altered lipid metabolism, and cachexia that directly impairs normal erythropoiesis.

3.2. Inflammatory Milieu and Catabolic Tissue Destruction

This systemic progression is heavily driven by *Pitta-pradhāna doṣa-duṣṭi*, [2] wherein *Pitta* predominance induces *dhātu-pāka* (tissue degeneration and breakdown). This mirrors the chronic inflammatory milieu observed in CKD, characterized by oxidative stress and cytokine excess that suppresses erythropoiesis, upregulates hepcidin, and causes functional iron deficiency. As these vitiated *doṣa* infiltrate and damage the deeper tissues (*doṣā dhātuṣu kupyanti*), they manifest as uremic toxin-mediated multisystem tissue injury, leading directly to bone marrow suppression and impaired red blood cell production.

3.3. Structural Weakening and Functional Impairment

The progressive infiltration results in *dhātu-śaithilya* (the structural and functional weakening of the *dhātu*), corresponding to a chronic catabolic state and impaired tissue integrity that dampens bone marrow responsiveness and defective haematopoiesis. Clinically, this functional incapacity and diminished physiological efficiency - referred to as गौरवं क्रियास्वसामर्थ्यात् (Chakrapāṇi) [3]- manifests as reduced oxygen delivery and metabolic inefficiency, producing hallmark symptoms of fatigue, exercise intolerance, and general weakness due to anemia.

3.4. Nutritional Impairment and Substrate Depletion

At the level of nutritive circulation and tissue building, multiple overlapping disruptions occur. *Pitta* destroys the nutritive components responsible for proper blood formation (रक्तपोषकरसस्य पित्तेन क्षपणात्) [4], reflecting the inflammatory destruction of the erythropoietic environment, cytokine-mediated suppression, and shortened erythrocyte survival. Furthermore, the complete failure to produce the nutritive essence necessary for *rakta dhātu* (रक्तपोषकसारभागानुत्पादात्) [5] correlates with defective erythropoietin synthesis and impaired iron utilization, resulting in inadequate red blood cell production despite available substrates. This is compounded by *rasa-duṣṭi* and *rasavaha srotoduṣṭi*, representing

defective primary nourishment and circulation that leads to fluid imbalance, toxin accumulation, and poor marrow nutrition.

3.5. Systemic Exhaustion and Biomarker Depletion

The severity of the interaction between *doṣa* and *dūṣya* (दोषदूष्यप्रदूषणात्) drives progressive pathology characterized by persistent inflammation, oxidative injury, functional iron deficiency, and erythropoietin resistance. Because *Ojas* is closely associated with *rakta dhātu* and overall vitality (ओजसो रक्तधातुरूपस्य ये गुणाः) [6] , its decline leads to a loss of oxygen-carrying capacity, systemic weakness, and impaired immunity. This *ojaḥ-kṣaya* progresses to *sneha-kṣaya* (loss of nourishment, stability, and anabolic support), mapping cleanly onto clinical malnutrition, hypoalbuminemia, and reduced substrate availability for erythropoiesis.

3.6. Phenotypic and Somatic Expressions

The quantitative depletion of the *Rakta-dhatu* directly translates to reduced red blood cell counts and haemoglobin concentrations characteristic of CKD-associated anemia. Concurrently, the depletion of *meda dhātu* and nutritional reserves reflects protein-energy wasting and cachexia, which further impair marrow function. The loss of tissue essence and regenerative capacity [8] corresponds to bone marrow hyporesponsiveness and systemic wasting. Furthermore, the weakness of the senses and neuromuscular apparatus due to *dhātu* depletion (शिथिलेन्द्रियः – दुर्बलेन्द्रियः) [7] accounts for the profound fatigue, lethargy, and cognitive dysfunction associated with the condition. Finally, abnormal skin coloration and pallor (वैवर्ण्यं भजते) occur due to vitiated *pitta* and *rakta-kṣaya*, representing reduced haemoglobin and impaired tissue oxygenation.

4. Integrated Pathomechanism (*Samprapti*)

The overarching narrative of disease progression is bound by the mutual interconnection of the *Medovaha*, *Rasavaha*, and *Mutravaha srotas*, framing CKD as a comprehensive multisystem metabolic-inflammatory disorder.

The complete integrated pathogenesis is thus established: *Mutravaha srotodusṭi* at the level of the *Vṛkka* triggers *Medovaha* dysfunction, which cascades into *Rasavaha* impairment and progressive *Rakta-kṣaya*, ultimately manifesting clinically as *Pāṇḍu* (anemia). In modern medical terms, this complete chain encapsulates how renal failure drives endocrine dysfunction, chronic inflammation, nutritional deficiency, oxidative stress, and marrow suppression into a unified, multifactorial clinical entity.

5. Discussion: Bridging Paradigms

Synthesizing classical Ayurvedic paradigms with modern nephrology bridges macroscopic clinical observations with microscopic molecular pathology. In contemporary terms, the Ayurvedic concept of *Pitta-pradhāna doṣa-duṣṭi* and *dhātu-pāka* directly mirrors the chronic low-grade systemic inflammation observed in CKD. This inflammatory milieu - driven by pro-inflammatory cytokines such as Interleukin-6 (IL-6), Tumour Necrosis Factor-alpha (TNF-alpha), and Interleukin-1 beta (IL-1β) - upregulates hepatic hepcidin, sequesters reticuloendothelial iron, and induces resistance to erythropoietin.

Similarly, the involvement of the *Medovaha srotas* maps cleanly onto uremic cachexia, dyslipidaemia, and protein-energy wasting, which collectively deplete the anabolic building blocks required for erythropoiesis. Recognizing CKD-associated anemia not merely as an isolated renal endocrine failure or primary hematologic defect, but as a complex multisystem metabolic-inflammatory disorder, reshapes the therapeutic horizon. Integrative protocols must move beyond isolated iron supplementation or recombinant human erythropoietin therapy to include strategies that pacify inflammatory pathways (*pitta-shamana*), clear metabolic and uremic toxins (*srotovishodhana*), and restore deep metabolic and tissue integrity (*agni-deepana* and *dhātu-poṣaṇa*).

6. Conclusion

Anemia in Chronic Kidney Disease is a multifaceted clinical challenge driven by renal endocrine exhaustion, chronic systemic inflammation, iron dysregulation, and progressive tissue catabolism. The classical Ayurvedic framework provides an advanced, holistic model - mapping *Mutravaha*, *Medovaha*, and *Rasavaha srotodusṭi* directly to modern pathophysiology - that deeply enriches our comprehension of systemic disease progression and offers a robust foundation for modern integrative clinical research and therapeutic design.

Conflicts of Interest: None

References

[1] Acharya Trikamji Y, editor, (3rd ed.). Charaka Samhita of Agnivesha, Vimana Sthana; Srotovimaniya Adhyayam: Chapter 5, Verse 8. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 250

[2] Acharya Trikamji Y, editor, (3rd ed.). Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16,

Verse 4. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526.

[3] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 4. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526

[4] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 6. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526

[5] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 6. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526.

[6] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 5. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526.

[7] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 4. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526.

[8] Acharya Trikamji Y, editor, (3rd ed.). Chakrapani Commentary on Charaka Samhita of Agnivesha, Chikitsa Sthana; Panduroga-Chikitsitam Adhyayam: Chapter 16, Verse 6. Varanasi: Chowkhambha Surabharati Prakashan, 2022; 526.

